Actions Panel
Thyroid Eye Disease: Current Perspectives on Multidisciplinary Management
CME Dinner Symposium
When and where
Date and time
Thursday, May 4 · 7 - 9pm PDT
Location
Sheraton Grand Seattle 1400 6th Ave Grand Ballroom, 2nd Floor Seattle, WA 98101
About this event
- 2 hours
- Mobile eTicket
Activity Chair
Terry J. Smith, MD
Frederick G.L. Huetwell Professor
Ophthalmology and Visual Sciences
Professor of Internal Medicine
University of Michigan Medical School
Ann Arbor, MI
Faculty
Giuseppe Barbesino, MD
Assistant Professor of Medicine
Harvard Medical School
Associate Physician
Massachusetts General Hospital
Boston, MA
Christian Nasr, MD, FACE
Chief of Endocrinology
Banner University Medical Group
Clinical Professor
Department of Internal Medicine
Division of Endocrinology
The University of Arizona
College of Medicine – Phoenix
Phoenix, AZ
Prem S. Subramanian, MD, PhD
Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology
Professor of Ophthalmology, Neurology, and Neurosurgery
University of Colorado School of Medicine
Vice Chair for Academic Affairs
Division Head, Neuro-Ophthalmology
University of Colorado Sue Anschutz-Rodgers Eye Center
Aurora, CO
Overview
Thyroid eye disease (TED) is a multifactorial autoimmune disease with widely varied signs and symptoms. It is believed to result from stimulation of several receptors located in the orbital fibroblasts and is usually associated with hyperthyroidism. However, 5% of patients with TED have hypothyroidism, and 5% have no sign of thyroid disease; thus, it is frequently misdiagnosed. Misdiagnosis can place patients at risk for disfigurement and permanent vision loss, because treatment is most effective during the initial active phase of the disease. Multidisciplinary management of the disease is necessary and involves endocrinologists, ophthalmologists, oculoplastic surgeons, as well as other healthcare providers. In this case-based CME activity, an expert panel will help healthcare professionals involved in the management of TED to recognize the pathogenesis of TED and the role of insulin-like growth factor-1 receptor, assess methods to improve differential diagnosis, review the benefits and limitations of available therapies, and implement practices and procedures that improve the multidisciplinary management of patients with this baffling and potentially devastating disease.
Agenda
7:00 PM
Registration and Dinner
7:30 PM
Introduction
Terry J. Smith, MD
7:35 PM
Thyroid Eye Disease: Insulin-like Growth Factor-1 Receptor as a Key Mediator of Disease
Terry J. Smith, MD
7:45 PM
Panel Discussion: Diagnosing a Hidden Disease
Moderated by Christian Nasr, MD
8:00 PM
Case Discussion: Differential Diagnosis
Giuseppe Barbesino, MD
8:05 PM
Thyroid Eye Disease Treatment: What the Endocrinologist Needs to Know
Prem S. Subramanian, MD, PhD
8:25 PM
Case Discussion: Treating Thyroid Eye Disease
Giuseppe Barbesino, MD
8:35 PM
Panel Discussion
Moderated by Terry J. Smith, MD
8:45 PM
Posttest and Question & Answer
9:00 PM
Conclusion
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Recognize the role of insulin-like growth factor-1 receptor in the pathogenesis of TED.
- Assess modalities that can improve the differential diagnosis of TED.
- Review the benefits and limitations of available therapies used in the treatment of TED.
- Implement practices and procedures that improve the multidisciplinary management of patients with TED.
Target Audience
The intended audience for this activity is endocrinologists and other healthcare professionals involved in the management of patients with TED.